GSPT1: A Promising Therapeutic Target for Cancer and ANT BIO PTE. LTD.'s Comprehensive Solutions

1. Concept: GSPT1 and Its Biological Role

G1 to S phase transition 1 (GSPT1), also known as eRF3a, is a critical protein encoded by the GSPT1 gene in humans. It functions as a key translation termination factor, forming a complex with eukaryotic release factor 1 (eRF1) to recognize stop codons on mRNA and facilitate the release of newly synthesized proteins from ribosomes. This process is indispensable for maintaining normal cellular protein homeostasis and physiological functions.

Beyond its role in translation termination, GSPT1 has emerged as a pivotal player in cancer biology. Abnormal expression of GSPT1 is frequently observed in tumor cells, and its downregulation can induce aberrant expression of key oncogenic proteins, inhibit tumor cell proliferation, or trigger apoptosis. This unique characteristic makes GSPT1 a highly attractive therapeutic target for cancer treatment, particularly in aggressive malignancies like glioblastoma.

2. Research Frontiers of GSPT1 in Cancer Therapy

Contemporary research on GSPT1 focuses on advancing targeted degradation strategies and expanding its therapeutic applicability. A key frontier is the development of dual-action molecules that combine PROTAC (Proteolysis-Targeting Chimeras) and molecular glue technologies, enabling concurrent degradation of GSPT1 and other oncoproteins (e.g., BTK) for synergistic anti-tumor effects. Another prominent direction involves optimizing GSPT1 degraders (e.g., CC-885) to enhance selectivity, reduce off-target effects, and improve pharmacokinetic properties. Additionally, research is exploring the role of GSPT1 in other cancer types beyond glioblastoma, such as lung, breast, and colorectal cancer, to broaden its therapeutic scope. Furthermore, the identification of resistance mechanisms to GSPT1-targeted therapies is a critical area, aiming to develop combination strategies that overcome treatment failure.

3. Research Significance of GSPT1

GSPT1 research holds profound implications for addressing unmet needs in cancer therapy:

• Novel therapeutic target: GSPT1’s essential role in tumor cell survival provides a unique vulnerability that can be exploited to develop effective treatments for refractory cancers like glioblastoma.
• Efficacy validation: Preclinical studies demonstrate that GSPT1 degradation or knockout inhibits tumor growth and extends survival in animal models, validating its therapeutic potential.
• Technological advancement: GSPT1-targeted therapies leverage cutting-edge PROTAC and molecular glue technologies, driving innovation in precision oncology.
• Clinical translation: The success of preclinical studies paves the way for clinical trials of GSPT1 degraders, offering new hope for patients with limited treatment options.
• Biomarker potential: GSPT1 expression profiling may aid in patient stratification, ensuring targeted therapies are administered to those most likely to benefit.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of GSPT1 in Cancer and Targeted Degradation

GSPT1’s Oncogenic Role

In cancer cells, GSPT1 overexpression supports uncontrolled proliferation by ensuring efficient translation of oncoproteins. Downregulating or degrading GSPT1 disrupts this balance, leading to the accumulation of truncated proteins, cell cycle arrest, and apoptosis.

Targeted Degradation Mechanisms

• PROTAC technology: PROTAC molecules bridge GSPT1 with an E3 ubiquitin ligase (e.g., CRBN), promoting ubiquitination and proteasomal degradation of GSPT1.
• Molecular glue technology: Small-molecule compounds induce a conformational change in GSPT1, enhancing its interaction with E3 ligases and triggering degradation.
• Dual-action strategies: Novel molecules combine PROTAC and molecular glue mechanisms to degrade GSPT1 and other oncoproteins simultaneously, maximizing anti-tumor efficacy.

4.2 Key Research Methods for GSPT1 Study

• Cell-based assays: Evaluation of GSPT1 knockout (KO) or degradation on tumor cell proliferation, apoptosis, and cell cycle using CRISPR/Cas9 technology and specific degraders (e.g., CC-885).
• In vivo models: Nude mouse xenograft models with glioblastoma cells (e.g., U87) to assess the efficacy of GSPT1-targeted therapies on tumor growth and survival.
• Protein-protein interaction assays: HTRF (Homogeneous Time-Resolved Fluorescence) technology to measure the formation of GSPT1-CRBN ternary complexes and validate degrader activity.
• Immunoblotting and immunostaining: Detection of GSPT1 expression, cleavage of apoptotic markers (e.g., PARP1, cleaved caspase-3), and proliferation markers (e.g., Ki-67) in cells and tumor tissues.
• Clinical sample analysis: Evaluation of GSPT1 expression in patient tumor samples and correlation with clinical outcomes.

4.3 Preclinical Study Validation (Case Study)

CC-885 Treatment in Nude Mice

U87 glioblastoma cells expressing iRFP720 were transplanted into nude mice, followed by intraperitoneal administration of CC-885 (50/100 mg/kg) or DMSO control on days 16, 18, 20, and 22. Tumor size was monitored via IVIS, and survival was analyzed using the Kaplan-Meier method.


GSPT1-KO and Rescued Cell Transplantation

GSPT1-KO U87 cells and Rescued GSPT1-KO cells (overexpressing FLAG-tagged GSPT1) were transplanted into nude mice. Survival analysis showed that GSPT1 deletion significantly extended survival, while rescued GSPT1 expression reversed this effect.

Apoptosis Analysis

WT and GSPT1-KO U87 cells were treated with staurosporine (62.5–500 nM) for 9 hours. Apoptosis was assessed via PARP1 cleavage. Additionally, cleaved caspase-3 immunostaining was performed on tumor tissues from xenograft models.

GSPT1 Expression in Patient Samples

GSPT1 expression was analyzed in glioblastoma patient samples via immunostaining and real-time RT-PCR. Kaplan-Meier curves showed no correlation between GSPT1 mRNA levels and overall survival in Kobe University and TCGA datasets.

4.4 Product Validation Data

GSPT1 Protein Activity and Purity

• Activity: HTRF assay showed GSPT1/CRBN ternary complex formation with EC₅₀ = 2.277 nM in the presence of CC-885.
• Purity: SDS-PAGE and HPLC confirmed >90% purity of GSPT1 GST Tag Protein.

GSPT1 Antibody Validation

The eRF3/GSPT1 Recombinant Rabbit mAb (S0B0414) was validated for WB, IP, and ICC, detecting both full-length and cleaved GSPT1.

E3 Ubiquitin Ligase (DDB1/CRBN Complex) Activity

HTRF assay showed lenalidomide-induced inhibition of DDB1/CRBN activity with IC₅₀ = 912.0 nM.

4.5 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. offers a comprehensive portfolio of reagents for GSPT1 research and drug development through its specialized sub-brands:

• Starter sub-brand (antibodies):
• eRF3/GSPT1 Recombinant Rabbit mAb (S0B0414, S-R325): Validated for Western blot (WB), immunoprecipitation (IP), and immunocytochemistry (ICC). It specifically detects full-length and cleaved GSPT1, enabling accurate quantification of GSPT1 expression and degradation in cells and tissues.
• UA sub-brand (recombinant proteins):
• GSPT1 GST Tag Protein, Human (UA080159): Expressed in E.coli, with >90% purity. It supports HTRF assays for ternary complex formation and degrader screening.
• E3 Ubiquitin Ligase Complexes: Including DDB1/CRBN Complex (UA080011), Cullin4A-RBX1-DDB1-CRBN Protein (UA080275), and Biotinylated CRBN/DDB1 Protein (UA080262), all expressed in baculovirus-insect cells. These complexes facilitate the study of GSPT1 degradation mechanisms and degrader validation.
• VHL/Elongin Complexes: Such as VHL/Elongin-C/Elongin-B Complex (UA080012) and Cullin2-RBX1-ElonginB/C-VHL Protein (UA080274), supporting research on alternative E3 ligase-mediated GSPT1 degradation.

All products comply with EU 98/79/EC, ISO9001, and ISO13485 certifications, ensuring high activity, purity, and reproducibility. They have been validated in preclinical studies, including GSPT1 degradation assays, apoptosis analysis, and in vivo tumor models.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and biopharmaceutical development through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, biopharmaceutical companies, and clinicians, accelerating the translation of scientific discoveries into life-saving cancer therapies.

6. Related Product List

7.AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.